News

Filter

Current filters:

vorinostat

1 to 9 of 13 results

Merck & Co's vorinostat shows early efficacy in MM

08-06-2009

Results from a Phase I study presented at the 14th annual meeting of the European Hematology Association…

lenalidomideMerck KGaANystatinOralRevlimidvorinostatZolinza

MSD withdraws MA for vorinostat in EU

23-02-2009

Merck Sharp & Dohme, the UK subsidiary of US drug major Merck & Co, has withdrawn its application for…

Merck KGaAvorinostatZolinza

Zolinza/Velcade combo enters Ph IIb MM trial

26-01-2009

The Multiple Myeloma Research Consortium has initiated a Phase IIb study of Merck & Co's Zolinza (vorinostat),…

bortezomiblenalidomideMerck KGaANystatinOralRevlimidThalidomideThalomidVelcadevorinostatZolinza

$1M Merck & Co research grant for NCCN

08-12-2008

The USA-based National Comprehensive Cancer Network recently received a $1.0-million research grant from…

Merck KGaAvorinostatZolinza

Merck & Co files MAA for vorinostat in CTCL

03-12-2007

US drug major Merck & Co has filed a Marketing Authorization Application with the European Medicines…

Merck KGaAvorinostatZolinza

30% of all CTCL patients see response with Zolinza, JCO study

30-07-2007

US drug major Merck & Co says that a trial of Zolinza (vorinostat) in patients with advanced, refractory…

Merck KGaANystatinOralvorinostatZolinza

1 to 9 of 13 results

Back to top